Get the Stockscreener App
7.23
0.28%
0.02
After Hours:
7.21
-0.02
-0.28%
Ataibeckley Inc stock is traded at $7.23, with a volume of 3.86M.
It is up +0.28% in the last 24 hours and up +39.85% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$7.21
Open:
$7.22
24h Volume:
3.86M
Relative Volume:
0.35
Market Cap:
$2.68B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.2296
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+0.14%
1M Performance:
+39.85%
6M Performance:
+101.96%
1Y Performance:
+75.06%
1-Day Range:
$7.22
$7.23
1-Week Range:
$7.18
$7.26
52-Week Range:
$3.265
$7.26
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.23 | 2.67B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Deutsche Bank Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $8 - moomoo.com
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Deutsche Bank Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $8 From $12 - marketscreener.com
AtaiBeckley Inc. Stock 12‑Month Price Target Cut to $8.83, Implies 22% Upside - TradingView
ATAI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
AtaiBeckley Inc reports results for the quarter ended June 30Earnings Summary - TradingView
AtaiBeckley Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com - Investing.com UK
Eli Lilly, AtaiBeckley filed US premerger forms July 29, got German approval July 30 - MLex
AtaiBeckley (NASDAQ: ATAI) backs $6.75 cash sale to Lilly plus CVR upside - Stock Titan
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know - Yahoo Finance
AtaiBeckley Inc. (ATAI): Investor Outlook with a 33.53% Potential Upside Amid Clinical Innovations - DirectorsTalk Interviews
Tracking Cathie Wood: Adding Intellia and SpaceX, Selling Off AtaiBeckley and Palantir - moomoo.com
Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? - Morningstar
AtaiBeckley Inc. (ATAI) Stock Analysis: Navigating Challenges with a Potential 33.53% Upside - DirectorsTalk Interviews
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. - Yahoo Finance
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly - True North Radio Network
BlackRock (ATAI holder) reports 24.99M ATAIBECKLEY shares, a 6.8% position - Stock Titan
AtaiBeckley(ATAI) Stock Options Chain | Quotes & News - Moomoo
Tracking Cathie Wood: Slashing AtaiBeckley and Figma, Betting on Gene-Editor Scribe Therapeutics - Moomoo
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too? - Stocktwits
Why Is ATAI Stock Soaring 59% After-Hours? - Stocktwits
AtaiBeckley Inc. Revenue Breakdown – MUN:B72 - TradingView
AtaiBeckley Inc. Revenue Breakdown – FWB:B72 - TradingView
ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly - Stocktwits
AtaiBeckley Inc. Revenue Breakdown – LS:A41WEP - TradingView
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Is AtaiBeckley (ATAI) A Bargain On Eli Lilly’s Takeover Deal? - simplywall.st
AtaiBeckley Inc. (ATAI) stock price, news, quote and history - Yahoo Finance UK
Form DEF 14A ATAI Beckley Inc For: 23 July By Investing.com - Investing.com Canada
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33% - Yahoo Finance
Key facts: Zepbound tops Wegovy; Novo sues; Lilly buys AtaiBeckley - TradingView
Lilly-AtaiBeckley Deal A Stamp Of Approval For Psychedelics - Law360
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? - TradingView
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal By Investing.com - Investing.com India
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal - Investing.com UK
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
Eli Lilly Acquires AtaiBeckley to Expand Mental Health Treatment Pipeline in $3.8 Billion Deal - Global Legal Chronicle
AtaiBeckley (NASDAQ:ATAI) shares reflect 18% implied value for acquisition milestone entitlements - TechStock²
ATAIBECKLEY INC : BERENBERG CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $7.45 FROM $14 - Bitget
AtaiBeckley (ATAI) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
ATAIBECKLEY INC : TD COWEN CUTS TO HOLD FROM BUY - Bitget
H.C. Wainwright Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $7.5 - Moomoo
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal - Endpoints News
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside - TradingView
TD Cowen Downgrades AtaiBeckley to Hold From Buy - Moomoo
Berenberg Downgrades AtaiBeckley to Hold From Buy, Adjusts Price Target to $7.45 From $14 - marketscreener.com
Lilly Joins Psychedelic Drug Race With AtaiBeckley Buyout – Merger Arbitrage Mondays (NASDAQ:ATAI) - Seeking Alpha
Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3 - TradingView
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - TradingView
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week? - Yahoo Finance
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.12%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):